Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 22, 2021, Kura Oncology, Inc. held its Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 23, 2021, the record date for the Annual Meeting, there were 66,273,680 shares of common stock outstanding, of which 60,588,421 shares of common stock were present in person or represented by proxy at the Annual Meeting.

At the Annual Meeting, stockholders:

(1) elected Troy E. Wilson, Ph.D., J.D. and Faheem Hasnain as Class I directors to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal;

(2) ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021; and

(3) approved, on an advisory basis, the compensation paid to our named executive officers as disclosed in the proxy statement.

The following sets forth detailed information regarding the final results of the voting for the Annual Meeting:

Proposal 1. Election of Directors



 Name of Director Elected         For            Withheld        Broker Non-Votes
Troy E. Wilson, Ph.D., J.D.     47,298,522       11,527,533           1,762,366
Faheem Hasnain                  40,856,592       17,969,463           1,762,366


Proposal 2. Ratification of the Selection of Independent Registered Public
Accounting Firm

    For          Against      Abstain      Broker Non-Votes
  60,568,240       17,484        2,697                 -

Proposal 3. Advisory Vote on Executive Compensation



    For            Against       Abstain       Broker Non-Votes
  57,074,798       1,744,029        7,228           1,762,366

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses